Pharmaceuticals Financial News

Shares of Glenmark Pharmaceuticals Ltd.(up 1.89 per cent), Lupin Ltd.(up 1.4 per cent), Mankind Pharma Ltd.(up 1.03 per cent), Ipca Laboratories Ltd.(up 0.7 per cent) and J B Chemicals & Pharmaceuticals Ltd.(up 0.68 per cent) ended the day as top gainers in the pack.

Shares of Natco Pharma Ltd.(up 2.48 per cent), Mankind Pharma Ltd.(up 2.05 per cent), J B Chemicals & Pharmaceuticals Ltd.(up 1.07 per cent), Granules India Ltd.(up 0.78 per cent) and Abbott India Ltd.(up 0.27 per cent) ended the day as top gainers in the pack.

Natco Pharma Ltd.(up 0.83 per cent), Mankind Pharma Ltd.(up 0.67 per cent), Torrent Pharmaceuticals Ltd.(up 0.23 per cent), Granules India Ltd.(up 0.15 per cent) and Ajanta Pharma Ltd.(up 0.13 per cent) were among the top gainers.

net worth of its billionaires nearly tripling to $905.6 billion in 10 years as of 2024. India now ranks third globally in total billionaire wealth, behind the United States and China, a UBS report highlighted. Rising sharply from $637.1 billion in 2023, this remarkable 42% growth rate in Indian billionaires’ wealth outpaces the global average and reflects India’s rapid economic transformation, propelled by family-led businesses and structural reforms propelled by the country’s government.

Stocks that rallied over 10% included, Indo Amines(13.38%), Bang Overseas(13.23%), Niva Bupa Health Ins(12.77%), HEG(11.21%), Wonderla Holidays(10.99%), Vippy Spinpro(10.55%), Zim Laboratories(10.51%) and Syschem(India)(10.17%).

Subscribe to enjoy similar stories. Natco Pharma Ltd isn’t your run-of-the-mill pharmaceutical company. It’s a story of calculated risks, high-stakes bets, and a fair bit of drama.

Cipla shares are in focus today after Samina Hamied and Rumana Hamied, promoters of the pharmaceutical company, exited by selling their 1.72% stake for Rs 2,111 crore through open market transactions. Investors including the Singapore government, Societe Generale, Abu Dhabi Investment Authority, BNP Paribas, BofA Securities, Citigroup, Morgan Stanley, Goldman Sachs, Norges Bank, UBS, and Copthall Mauritius bought stakes in Cipla. According to block deal data available on the National Stock Exchange (NSE), Samina sold 89.54 lakh shares of Cipla, while Rumana Hamied offloaded 49.43 lakh shares, amounting to a 1.11% and 0.61% stake, respectively.

Artificial intelligence is changing the way industries do business

The NSE Nifty index was trading 7.4 points down at 24123.7, while BSE Sensex was 109.35 points at 79693.44 at the time of writing this report.

Donald Trump prepares for his second term as US President, his aggressive trade stance is already creating ripples in the global economy. A key element of his protectionist policies is the threat of imposing 100% tariffs on BRICS countries, including India, if they move away from using the US dollar in international transactions. This bold stance, declared through a scathing social media post, could have severe consequences for India’s exports, particularly in critical sectors such as pharmaceuticals, textiles, and information technology. Trump’s remarks come in response to discussions among BRICS nations, which include Brazil, Russia, India, China, and South Africa, regarding the possibility of reducing their reliance on the US dollar for trade. A summit held in Russia in October focused on increasing local currency transactions, a move that Trump has now vowed to challenge. “The idea that the BRICS Countries are trying to move away from the Dollar while we stand by and watch is OVER,” Trump wrote, warning that any country attempting to replace the dollar with another currency would face significant tariff hikes. Also Read: Trump threatens 100% tariff on BRICS countries over currency plans

Sun Pharmaceutical Industries Ltd on Thursday said the Ministry of Corporate Affairs has levied penalties on certain past and present directors and officials, including CMD Dilip Shanghvi, for non-disclosure and not obtaining approval of its board and shareholders for certain related party transactions. The company has received an order from the Regional Director, North Western Region, Ministry of Corporate Affairs, for alleged violations of certain provisions of the Companies Act, 2013, Sun Pharmaceutical Industries said in a regulatory filing. «A total combined compounding fee is levied on certain past and present directors/officers of the company — Dilip Shanghvi (Rs 9.5 lakh), Sudhir Valia (Rs 9 lakh); Sailesh Desai (Rs 9 lakh); K Subramanian (Rs 1.5 lakh); Uday Baldota (Rs 6 lakh) and C Muralidharan (Rs 1.5 lakh),» the filing said. This matter pertains to the earlier investigation carried out by SEBI, in which a settlement was reached with the markets regulator in February 2021 without admission or denial of guilt; however, on the same matter, the Ministry of Corporate Affairs also initiated an investigation in parallel in 2019, it added.

Subscribe to enjoy similar stories. New Delhi: Robust sales growth recorded by the Indian government’s generic pharmacy model will put pressure on trade margins in the retail medicine market because of the affordability and quality of the drugs sold, a top official said. The quality certified generic medicines sold at kendras (centres) operating under the Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) help to moderate the prices of medicines and create a benchmarking effect, Arunish Chawla, secretary of the Department of Pharmaceuticals, said in an interview toMint.

Subscribe to enjoy similar stories. India-China trade data for 2023 reveals a widening discrepancy, with India's reported imports from China falling significantly short of China's export figures, raising concerns over potential anomalies such as under-invoicing, misclassification, and inconsistent reporting practices.

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning

Granules India Ltd.(up 1.28 per cent), Glenmark Pharmaceuticals Ltd.(up 0.87 per cent), Biocon Ltd.(up 0.76 per cent), J B Chemicals & Pharmaceuticals Ltd.(up 0.51 per cent) and Alkem Laboratories Ltd.(up 0.11 per cent) were among the top gainers.

Shares of Laurus Labs Ltd.(up 3.8 per cent), Torrent Pharmaceuticals Ltd.(up 3.15 per cent), Granules India Ltd.(up 2.78 per cent), Sanofi India Ltd.(up 2.58 per cent) and Divi's Laboratories Ltd.(up 2.34 per cent) ended the day as top gainers in the pack.

The report also highlighted that Indian Pharmaceutical Market (IPM) grew by 8 per cent YoY, with chronic therapies showing a 9 per cent increase. However, acute therapies experienced modest growth of 4 per cent due to a weak season for these segments. It said «The pharmaceutical universe under our coverage reported Q2FY25 growth of 10.2 per cent YoY and 1.7 per cent QoQ, driven by robust growth in North America (10.8 per cent YoY) and the India business (9.8 per cent YoY)».

Donald Trump has far-reaching implications for global trade and geopolitics. According to a report by Motilal Oswal, this policy carries mixed outcomes for exporters worldwide because it is designed to prioritize U.S. manufacturing by reducing imports, particularly from China. For India, Trump's policies present both opportunities and challenges. The Indo-Pacific defense strategy could strengthen U.S.-India collaboration, opening doors for Indian businesses in sectors such as pharmaceuticals and defense.

Subscribe to enjoy similar stories. Tata Capital Healthcare Fund (TCHF) is planning to increase the ticket size of each of its investments to around $25 million, from $10-18 million currently, the private equity (PE) fund’s managing partner Visalakshi Chandramouli said, as demand for healthcare in the world's fifth-largest economy grows. The fund is also betting on domestic pharmaceutical companies that target global markets.

Subscribe to enjoy similar stories. New Delhi: India's production sops programme which powered a ₹13 trillion manufacturing boom may not add any more sectors soon in the wake of slowing disbursements, two people aware of the matter said.

Subscribe to enjoy similar stories. Mumbai: Softening prices of active pharmaceutical ingredients (API) are likely to stabilise in the months ahead and bring relief to Indian manufacturers, but they will still have to improve their operational efficiency to compete against Chinese rivals, industry executives and analysts said. API prices have been falling for the past 12-15 months, driven mainly by sharp price cuts by Chinese companies, which is impacting the bottom line of Indian API companies.